Data From Investigational Use of PROCRIT(R) (Epoetin alfa ... MarketWatch - Nov 7, 2008 PROCRIT is used for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and ...
Student searches world for person to save his life Greenfield West Allis Now, WI - Nov 26, 2008 Routine screening at the donation center revealed David was anemic; his iron count was too low for him to donate blood. David confided to his parents that ...
Head and Neck Cancers WTVQ, KY - Nov 24, 2008 This syndrome is characterized by severe anemia and leads to difficulty swallowing due to webs of tissue that grow across the upper part of the esophagus. ...
Blood Disorders in the Elderly Journal of American Medical Association (subscription), IL - Nov 11, 2008 ... including erythropoiesis, hematopoiesis, iron, vitamin B 12 , anemia, cancer chemotherapy, acute myeloid leukemia, acute lymphoblastic leukemia, ...
Martinez conquers cancer Lompoc Record, CA - Nov 10, 2008 Martinez did not have to undergo any chemotherapy or radiation because they had found the lump in its infancy and the surgeon was able to remove it all. ...
3SBio Inc. Q3 2008 Earnings Call Transcript Seeking Alpha, NY - Nov 11, 2008 Treatment of anemia associated with the chemotherapy in cancer patients. Once proved, this high dose EPIAO is expected to be the only one of its kind in the ...SSRX
3SBio Inc. Announces Third Quarter 2008 Results Earthtimes (press release), UK - Nov 10, 2008 ... expected to provide us with the distinct competitive advantage of offering a convenient, once-a-week treatment option to anemic chemotherapy patients. ...SSRX
3SBio Inc. Announces Third Quarter 2008 Results PR Newswire (press release), NY - Nov 10, 2008 ... expected to provide us with the distinct competitive advantage of offering a convenient, once-a-week treatment option to anemic chemotherapy patients. ...SSRX
Source: Google News
Recent News and Articles on the Keywords: intravenous + 1,340 + web Related to the article below (Last Update: 8/7/2008)
EKR Therapeutics Wins Approval for Cardene Intravenous Bags RedOrbit, TX - Aug 5, 2008 EKR Therapeutics has received approval from the FDA for Cardene IV premixed injection, a patented, ready-to-use, single use intravenous bag for the ...
Cara Therapeutics Completes Phase I Study of Pain Drug RedOrbit, TX - The drug candidate was safe and well-tolerated after intravenous infusion, and resulted in plasma levels of CR845 expected to be associated with clinical ...
Fasting Malik hospitalised after health deteriorates Thaindian.com, Thailand - ?He has refused intravenous feeding, but we are giving him life-saving drugs through an intravenous line. He is already suffering from a heart condition and ...
Charity teams with doctor to battle substance abuse Thousand Oaks Acorn, USA - Meth detox requires an intravenous drug that's extremely expensive. Akrey and Schaffner said they hope to start treating meth addicts soon. ...
Alternative Therapies I Lew Rockwell, CA - Next week, researchers from Stanford will publish the results of a study in mice in which intravenous Vitamin C is active against cancer. ...
Formulation-related problems associated with intravenous drug delivery - SH Yalkowsky, JF Krzyzaniak, GH Ward - Journal of Pharmaceutical Sciences, 1998 - doi.wiley.com ... Phlebitis is a fairly common and potentially very serious side effect of intravenous
therapy. Boon et al. ... Vol. 87, No. 7, July 1998 Published on Web 06/05/1998 ...
Nucleus Accumbens Long-Term Depression and the Expression of Behavioral Sensitization - K Brebner, TP Wong, L Liu, Y Liu, P Campsall, S … - Science, 2005 - sciencemag.org ... that does not support current Web standards. ...1340 - 1343 DOI: 10.1126/science.1116894. ...
sensitization to psychostimulant drugs after intravenous (iv) injection ...
Pharmaceutical properties of related calanolide compounds with activity against human … - RA Newman, W Chen, TL Madden - Journal of Pharmaceutical Sciences, 1998 - doi.wiley.com ... 9, September 1998 Published on Web 08/05/1998 ... in each drug following oral administration
as compared to intravenous administration. ... 1990, 322, 1333 - 1340. ...
NEWSLETTER DEVELOPMENTS AND DISTRIBUTION - CM OF - nppg.scot.nhs.uk ... clinical biochemistry, public health etc., has a web page at ... The role of intravenous
midazolam in the management of ... 1994; 22(8): 1340 - 1341 22.Kolul RL et al. ... -
Source: Google Scholar
Chemotherapy-induced anemia: benefits of Aranesp with intravenous Iron
A study suggests that Aranesp ( Darbepoetin alfa ) administered every three weeks with intravenous ( IV ) iron has the potential to further enhance the effectiveness of increasing patient hemoglobin levels to the recommended target of greater than or equal to 11 g/dL and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
Interim results from 196 patients in this Phase 3b study demonstrated that, among patients receiving 500 mcg Aranesp administered every three weeks in combination with IV iron ( n= 100 ), 94 percent achieved the target hemoglobin level of greater than or equal to 11 g/dL between week five and the end of treatment. In the group who received Aranesp and iron administered according to standard practice ( oral iron or no iron ) ( n= 96 ), 89 percent of patients achieved the target hemoglobin level.
Fewer patients in the group administered IV iron received a red blood cell transfusion between week five and the end of treatment compared to patients in the group receiving standard iron administration ( 12 percent versus 25 percent ).
Treatment-related adverse events were similar between the two groups ( six percent in the IV iron group compared to three percent in the oral or no iron group ) and were consistent with the adverse event profile for this population of anemic chemotherapy patients receiving Aranesp.
Cardiovascular and thromboembolic adverse events were reported in few patients ( six patients in each group ) and were not associated with increases in hemoglobin levels.
Source: 2006 American Society of Clinical Oncology ( ASCO ) Annual Meeting
